Abstract:

Benign esophageal stricture is a common disease caused by chronic non⁃tumor esophageal injury and fibrosis. With the rapid increase of endoscopic submucosal dissection（ESD）and radical esophageal surgery for early esophageal cancer in recently years，the incidence of benign esophageal stricture is also increasing. Endo⁃ scopic dilation is the first choice. However，for refractory esophageal benign stricture，the repeated dilation often leads to procedure⁃related perforation and bleeding with lower efficiency. MMC was originally an anti⁃tumor agent， and it was also used as an anti⁃fibroproliferative drug. MMC has been used in the treatment of benign esophageal stricture for nearly 20 years，and its safety and effectiveness have been confirmed. However，the delivery method and concentration varied greatly in different reports. Therefore，this article will review the clinical application of MMC in benign esophageal stricture. 

Key words:

mitomycin C, benign esophageal stricture, endoscopic dilation